The influence of alendronate therapy on the quality of life in postmenopausal women with reduced bone mineral density
DOI:
https://doi.org/10.20883/jms.2017.212Keywords:
HRQoL, alendronate therapy, postmenopausal women, osteoporosis, QUALEFFO – 41, WHOQOL-100,Abstract
Introduction and objective: The aim of the study was to evaluate the effect of treatment on the quality of life (QoL) in postmenopausal women characterized by the reduced BMD.
Material and methods: Postmenopausal women (n=102), mean age (65.09±5.6 years) were included in this study. The participants were divided into two groups, depending on the treatment or lack of treatment. For assessment of their QoL, QUALEFFO-41 scale and WHOQOL-100 scale were used.
Results: Mean values of the QUALEFFO-41 scale of women who used alendronate were significantly lower than those found in subjects not treated with this drug in the following areas: pain (p=0.03), ADL (p=0.03), jobs around the house (p=0.01), mobility (p=0.01), health perception (p=0.03), emotional function (p= 0.007) and total QoL (p=0.005). The mean values of the WHOQOL-100 scale almost did not differ significantly between both groups of studied patients. An exception was the level of independence, with mean values of women not receiving bisphosphonates being significantly higher than those of patients using bisphosphonates therapy (p=0.04).
Conclusions. Quality of life assessment of women with osteoporosis and osteopenia using a specific scale and general scale can be a valuable clue in the planning of treatment, nursing care and psychological care.
Downloads
References
Cumming RG, Nevitt MC, Cummings SR. Epidemiology of hip fractures. Epidemiol Rev. 1997;19:244–257.
Cooper C, Atkinson EJ, Jacobsen SJ et al. Population-based study of survival after osteoporotic fractures. Am J Epidemiol. 1993;137:1001–1005.
Stompór T, Zabłocki M, Łesiów M. Osteoporosis in mineral and bone disorders of chronic kidney disease. Pol Arch Med Wewn. 2013;123:314–320.
Głuszko P, Lorenc RS, Karczmarewicz E, et al. Polish guidelines for the diagnosis and management of osteoporosis: a review of 2013 update. Pol Arch Med Wewn. 2014;124:255–263.
Lakatos P, Balogh A, Czerwinski E, et al. Members of the “3rd Summit on Osteoporosis—Central and Eastern Europe (CEE)”. New considerations on the management of osteoporosis in Central and Eastern Europe (CEE): summary of the “3rd Summit on Osteoporosis-CEE”, November 2009, Budapest, Hungary. Arch Osteoporos. 2011;6:1–12.
Lorenc RS, Resch H, on behalf of the Members of the “2nd Summit on Osteoporosis—Central and Eastern Europe (CEE)”. Management of osteoporosis in central and eastern Europe (CEE): conclusions of the “2nd Summit on Osteoporosis-CEE”, 21-22 November 2008, Warsaw, Poland. Arch Osteoporos. 2009;4:1–8.
Harris ST, Reginster JY, Harley C et al. Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: the eValuation of IBandronate Efficacy (VIBE) database fracture study. Bone. 2009;44:758–765.
McClung MR, Geusens P, Miller PD et al. Effects of risedronate on the risk of hip fracture in elderly women. N Engl J Med. 2001;44:333–340.
Sebba AI, Emkeyb RD, Kohlesc JD, Sambrookd PN. Ibandronate dose response is associated with increases in bone mineral density and reductions in clinical fractures: Results of a meta-analysis. Bone. 2009;4:423–427.
Yildirim K, Gureser G, Karatay S et al. Comparison of the effects of alendronate, risedronate and calcitonin treatment in postmenopausal osteoporosis. J Back Musculoskelet. 2005;18:85–89.
Fleisch H. Bisphosphonates in bone disease. From the laboratory to the patient. The Parthenon Publishing Group, New York,1997, p. 12.
Sambrook PN, Silverman SL, Cauley JA et al. Health-related quality of life and treatment of life and treatment of postmenopausal osteoporosis: results from the HORIZON-PFT. Bone. 2011;48:1298–1304.
Flood E, Beusterien K, Green H et al. Psychometric evaluation of the Osteoporosis Patient treatment Satisfaction Questionnaire (OPSAT-QTM), a novel measure to assess satisfaction with bisphosphonates treatment in postmenopausal women. Health Qual Life Outcomes. 2006;4:42.
Ki Won OH, Deog-Yoon Kim, Yil- Seob Lee, Moo IL Kang. Osteoporosis Patient Treatment Satisfaction Questionnaire in postmenopausal women intermittently treated with oral bisphosphonates: the BRAVO study. J Bone Miner Metab. 2012;30:359–366.
Bączyk G, Opala T, Kleka P, Chuchracki M. Multifactorial analysis of risk factors for reduced bone mineral density among postmenopausal women. Arch Med Sci. 2012;8:332–341.
Li M, Zhang ZL, Liao EY. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis. Menopause. 2013;20:72–76.
Marcinowska-Suchowierska E, Walicka M. Leczenie farmakologiczne osteoporozy z wykorzystaniem bisfosfonianów – dla kogo, jakie, jak długo? Reumatologia. 2014;52(4):238–246.
Schipper H, Clinch J, Powell V. Definitions and conceptual issues. In: Spilker B (ed) Quality of Life Assessments in Clinical Trials, Raven Press, New York, pp 1992;11.
World Health Organization Study Group. Assessment of fracture risk and its application to screening for post-menopausal osteoporosis. In WHO Technical Report Series. No, 843 WHO, Geneva. 1994.
Blake GM, Naeem M, Boutros M. Comparison of effective dose to children and adults from dual X-ray absorptiometry examinations. Bone. 2006;38:935–942.
Kelly TL Sp, von Stetton E. Performance evaluation of a multi-detector DXA device. J Bone Miner Res. 1991;6(Suppl. 1):168.
Bączyk G, Opala T, Kleka P. Quality of life in postmenopausal women with reduced bone mineral density: psychometric evaluation of the Polish version of QUALEFFO -41. Arch Med Sci. 2011;7:476–485.
Lips P, Cooper C, Agnusdei D et al. Quality of life in patients with vertebral fractures: validation of the Quality of Life Questionnaire of the European Foundation for Osteoporosis (QUALEFFO), Working Party for Quality of Life of the European Foundation for Osteoporosis. Osteoporos Int. 1999;10:150–160.
Wołowicka L, Jaracz K. Polish version WHOQOL-100 and WHOQOL-Bref. In: Wołowicka L (ed) Quality of life in medical sciences, AM, Poznan. 2001, pp 235.
Dennison EM, Jameson K A, Syddall HE et al. Bone health and deterioration in quality of life among participants from the Hertfordshire Cohort Study. Osteoporos Int. 2010;21:1817–1824.
Dennison EM, Syddall HE, Statham C et al. Relationships between SF-36 health profile and Bone Mineral Density: the Hertfordshire Cohort Study. Osteoporos Int. 2006;17:1435–1442.
Iwamoto J, Makita K, Sato T, Takeda T, Matsumoto H. Alendronate is more effective than elcatonin in improving pain and quality of life in postmenopausal women with osteoporosis. Osteoporos Int. 2011;22:2735–2742.
Panico A, Lupolo GA, Marciello F et al. Teriparatide vs. Alendronate as a treatment for osteoporosis: Changes in biochemical markers of bone turnover, BMD and quality of life. Med Sci Monit. 2011;17:CR442–8.
Ferreira NO, Arthuso M, Silva R et al. Quality of life in women with postmenopausal osteoporosis: Correlation between QUALEFFO 41 and SF-36. Maturitas. 2009;62:85–90.
Sezer N, Tomruk-Sutbeyaz S, Kibar S, Koseoglu F, Aras M. Determinants of quality of life in postmenopausal osteoporosis. FTR Bil Der JPMR Sci. 2009;12:19.
Lewiecki EM, Babbitt AM, Piziak VK, Ozturk ZE, Bone HG. Adherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: a 12-months, open label, prospective evaluation. Clin Ther. 2008;30:605–621.
Kastelan D, Lozo P, Stamenkovic D, et al. Preference for weekly and monthly bisphosphonates among patients with postmenpausal osteoporosis: results from the Croatian PROMO Study. Clin Rheumatol. 2009;28:321–326.
Downloads
Published
Issue
Section
License
Copyright (c) 2017 Grażyna Bączyk, Dorota Formanowicz, Paweł Kleka, Włodzimierz Samborski
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
